Assessing of Antibiotic Resistance in the Phage-Plasmids of Klebsiella pneumoniae and Its Inhibitory Compound


Creative Commons License

Silme R. S.

Diğer, ss.1-17, 2025

  • Yayın Türü: Diğer Yayınlar / Diğer
  • Basım Tarihi: 2025
  • Sayfa Sayıları: ss.1-17
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Antibiotic resistance in Klebsiella pneumoniae pose an increasing risk for human health worldwide. A continuous monitoring the distribution of virulence and resistanceassociated genes is required for early detection of successful K. pneumoniae lineages. In this study, whole genome sequences data was used to characterize phage-plasmids of K. pneumoniae isolated from different countries and its inhibitory compound was investigated for phage-plasmids.

Methods: Whole genomes sequences of 15 genetically similar phage-plasmids of K. pneumoniae strains were selected according to BlastN analysis. Antibiotic resistance and virulence associated genes were screened by using ResFinder, PhageAI, PlasmidFinder, PHASTEST and PhageGE tools. Later on, whole genome sequences of phage-plasmids were analysed for a stable region in the genome by MAUVE analysis. The stable region encoding protein and its candidate inhibitor molecule was analysed to observe the interaction between protein and inhibitory compound by molecular docking studies.

Results: Various antibiotic resistance genes involving Aminoglycosides and Beta-lactams were detected in screened 7 of 15 phage-plasmids. All the plasmids had Salmonella SSU5 prophage. Phylogenetic analysis results showed the phage-plasmid belonging to India or China. MAUVE analysis indicated that the region encoding Replication protein A were common stable region. Molecular docking studies proved an interaction occurring within Replication protein A and a derivate of Fabimycin.

Conclusions: The analysis showed that Replication protein A could be a target site for new drug designing. Additionally, Fabimycin could be used to control both phage-plasmids and its host K. pneumonia, which could affect the severity and incidence of K. pneumoniae infections. Further studies in vitro and clinical studies could confirm present findings and also enhance our knowledge on phage-plasmids and new treatments against K. pneumoniae infections.

Objectives: Antibiotic resistance in Klebsiella pneumoniae pose an increasing risk for human health worldwide. A continuous monitoring the distribution of virulence and resistanceassociated genes is required for early detection of successful K. pneumoniae lineages. In this study, whole genome sequences data was used to characterize phage-plasmids of K. pneumoniae isolated from different countries and its inhibitory compound was investigated for phage-plasmids.

Methods: Whole genomes sequences of 15 genetically similar phage-plasmids of K. pneumoniae strains were selected according to BlastN analysis. Antibiotic resistance and virulence associated genes were screened by using ResFinder, PhageAI, PlasmidFinder, PHASTEST and PhageGE tools. Later on, whole genome sequences of phage-plasmids were analysed for a stable region in the genome by MAUVE analysis. The stable region encoding protein and its candidate inhibitor molecule was analysed to observe the interaction between protein and inhibitory compound by molecular docking studies.

Results: Various antibiotic resistance genes involving Aminoglycosides and Beta-lactams were detected in screened 7 of 15 phage-plasmids. All the plasmids had Salmonella SSU5 prophage. Phylogenetic analysis results showed the phage-plasmid belonging to India or China. MAUVE analysis indicated that the region encoding Replication protein A were common stable region. Molecular docking studies proved an interaction occurring within Replication protein A and a derivate of Fabimycin.

Conclusions: The analysis showed that Replication protein A could be a target site for new drug designing. Additionally, Fabimycin could be used to control both phage-plasmids and its host K. pneumonia, which could affect the severity and incidence of K. pneumoniae infections. Further studies in vitro and clinical studies could confirm present findings and also enhance our knowledge on phage-plasmids and new treatments against K. pneumoniae infections.